Treatment patterns and outcomes of pediatric rhabdomyosarcoma in a resource-limited setting: A retrospective study from a tertiary hospital in Ethiopia
- 1Addis Ababa University School of Medicine
Abstract
Background: Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite excellent survival in high-income countries, data on treatment and outcomes remain limited in resource-limited settings. The aim of this study was to assess treatment patterns and survival outcomes of pediatric RMS in Ethiopia. Methods: We conducted a retrospective study of newly diagnosed pediatric RMS patients evaluated at Tikur Anbessa Specialized Hospital from January 2021 to September 2025. Data were extracted from medical records, and treatment patterns and survival were assessed using descriptive and Kaplan-Meier analyses. Results: A total of 94 pediatric patients with rhabdomyosarcoma were included. The median age at diagnosis was 4.0 years (IQR: 3.0-6.3 years). Of these patients, 23.4% were classified as low-risk, 61.7% as intermediate-risk, and 14.9% as high-risk. Multimodality treatment was delivered to 59.6% of patients, while 33.0% received chemotherapy alone and 7.4% received no treatment. At diagnosis, curative treatment intent was planned for 83% of patients, but only 71.8% ultimately received it. Treatment received varied by risk group: most (90.0%) low-risk patients got curative treatment, while only 64.3% of intermediate-risk patients got curative treatment intent. No high-risk patients received curative treatment.At a median follow-up of 21.0 months (95% CI: 17.6-24.4 months), median overall survival and event-free survival were 23.0 and 15.0 months, respectively. The 1-year and 2-year overall survival rates were 70% and 42%, respectively, while the corresponding event-free survival rates were 59% and 33%. In multivariable Cox regression, treatment modality (p < 0.001) and total chemotherapy cycles (p =0.001) remained independently associated with overall survival, while risk group was not significant (p =0.14). Conclusion: Pediatric rhabdomyosarcoma in Ethiopia presents with a high rate of high-risk disease. Multimodality therapy and completion of chemotherapy cycles are key determinants of improved survival. These findings highlight the urgent need for early detection, improved access to multimodal treatment, and strategies to reduce treatment abandonment and improve treatment completion rates in resource-limited settings. Larger prospective studies are warranted to validate these findings and guide evidence-based practice.
Related
- Post-Recurrence Treatment Patterns and Outcomes After Curative-Intent Multimodality Strategy in Patients with Pleural Mesothelioma: A Retrospective Cohort Study
- Modern endoscopic treatment of pediatric urolithiasis: early outcomes of a single-center retrospective study
- Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
- Clinicopathological Profile, Treatment Patterns and Documented Clinical Outcomes of Women with Breast Cancer at Shendi Hospital, Sudan: A Retrospective, Single-Center, Hospital-Based Cross-Sectional Study.
- Comparative perioperative and follow-up outcomes of three laparoscopic reconstructive procedures for pediatric duplex kidney : A retrospective cohort study
BibTeX
@misc{semayneh2026treatment,
title = {{Treatment patterns and outcomes of pediatric rhabdomyosarcoma in a resource-limited setting: A retrospective study from a tertiary hospital in Ethiopia}},
author = {S. W. Semayneh and B. T. Liyewu and K. G. Yohannes and G. A. Mekonnen and A. Fekadu and S. Zerihun and M. A. Aman and D. T. Reta and H. W. Jemil},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.26366799},
url = {https://www.medrxiv.org/content/10.64898/2026.10.29.26366799v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Treatment patterns and outcomes of pediatric rhabdomyosarcoma in a resource-limited setting: A retrospective study from a tertiary hospital in Ethiopia
AU - S. W. Semayneh
AU - B. T. Liyewu
AU - K. G. Yohannes
AU - G. A. Mekonnen
AU - A. Fekadu
AU - S. Zerihun
AU - M. A. Aman
AU - D. T. Reta
AU - H. W. Jemil
PY - 2026
DA - 2026/10/29
PB - medRxiv
DO - 10.64898/2026.10.29.26366799
UR - https://www.medrxiv.org/content/10.64898/2026.10.29.26366799v1
AB - Background: Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. Despite excellent survival in high-income countries, data on treatment and outcomes remain limited in resource-limited settings. The aim of this study was to assess treatment patterns and survival outcomes of pediatric RMS in Ethiopia. Methods: We conducted a retrospective study of newly diagnosed pediatric RMS patients evaluated at Tikur Anbessa Specialized Hospital from January 2021 to September 2025. Data were extracted from medical records, and treatment patterns and survival were assessed using descriptive and Kaplan-Meier analyses. Results: A total of 94 pediatric patients with rhabdomyosarcoma were included. The median age at diagnosis was 4.0 years (IQR: 3.0-6.3 years). Of these patients, 23.4% were classified as low-risk, 61.7% as intermediate-risk, and 14.9% as high-risk. Multimodality treatment was delivered to 59.6% of patients, while 33.0% received chemotherapy alone and 7.4% received no treatment. At diagnosis, curative treatment intent was planned for 83% of patients, but only 71.8% ultimately received it. Treatment received varied by risk group: most (90.0%) low-risk patients got curative treatment, while only 64.3% of intermediate-risk patients got curative treatment intent. No high-risk patients received curative treatment.At a median follow-up of 21.0 months (95% CI: 17.6-24.4 months), median overall survival and event-free survival were 23.0 and 15.0 months, respectively. The 1-year and 2-year overall survival rates were 70% and 42%, respectively, while the corresponding event-free survival rates were 59% and 33%. In multivariable Cox regression, treatment modality (p < 0.001) and total chemotherapy cycles (p =0.001) remained independently associated with overall survival, while risk group was not significant (p =0.14). Conclusion: Pediatric rhabdomyosarcoma in Ethiopia presents with a high rate of high-risk disease. Multimodality therapy and completion of chemotherapy cycles are key determinants of improved survival. These findings highlight the urgent need for early detection, improved access to multimodal treatment, and strategies to reduce treatment abandonment and improve treatment completion rates in resource-limited settings. Larger prospective studies are warranted to validate these findings and guide evidence-based practice.
ER -